Lucero joins Nanoscale Drug Testing consortium
The consortium aims to develop a “near-patient drug development” strategy that includes using 3D cell models comprised of patient-derived cells. The strategy will reduce clinical failures, enable the development of more effective treatments at a lower cost, and allow the right drug leads to be matched with the right patient subgroup.